Latest News

Scope for inflammatory marker laboratory tests to move into community settings

OXFORD, UNITED KINGDOM, UNITED KINGDOM - Apr 30, 2019 - The significant demand for inflammatory marker laboratory tests in general practice highlights an untapped opportunity for point-of-care diagnostics in the community, suggests research from the NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-operative.

Reported in the Journal of Clinical Pathology, the study finds that GP practices typically request 36 CRP tests and 72 neutrophil count tests per week.

From the Universities of Oxford, Birmingham and KU Leuven in Belgium, the research team analysed data more than 1.14 million C-Reactive Protein (CRP) and neutrophil count test requests in over 435,000 patients from 69 general practices in Oxfordshire between 2014-16.

This corresponds roughly to one CRP test requested per five people per year and one neutrophil test requested per three people per year. More than 70% of those initially tested would require another test in a three-year period.

CRP and neutrophil count are important biomarkers of inflammation used by general practitioners. CRP levels in the blood typically rise rapidly in response to infection and inflammatory conditions. A raised neutrophil count indicates abnormal inflammation which may result from acute bacterial infection, while a low neutrophil count can be a warning that a patient is at higher risk of serious bacterial infection, which can be a complication of treatments such as chemotherapy.

GPs often have to wait up to 24 hours to receive test results from central laboratories, despite the availability of existing point-of-care equivalents.

Lead author Dr José Ordóñez-Mena, Medical Statistician in Oxford University’s Nuffield Department of Primary Care Health Sciences, commented: “Inflammatory marker laboratory tests are requested frequently in the community, particularly in combination, with many patients needing repeat tests. We also find that CRP test requests are becoming increasingly common in older patients.  Given that these tests can now be provided by point-of-care technologies, there is scope for this testing to start moving into the community, carried out by general practitioners for results within minutes, rather than being performed by central laboratories.”

Read more in the Journal of Clinical Pathology: https://jcp.bmj.com/content/early/2019/04/16/jclinpath-2018-205688.full

ENDS

NOTES TO EDITORS:

Contact Dan Richards-Doran, Senior Communications Manager, Nuffield Department of Primary Care Health Sciences, University of Oxford 01865 617870 dan.richards-doran@phc.ox.ac.uk

The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:

  • Funds, supports and delivers high quality research that benefits the NHS, public health and social care
  • Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
  • Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
  • Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
  • Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding.

This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. www.nihr.ac.uk/patientdata

The NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-Operative brings together experienced health researchers, industry, end users and clinical experts in the development and evaluation of diagnostics tests that transform community healthcare through studies in NHS settings. https://www.community.healthcare.mic.nihr.ac.uk